financetom
Business
financetom
/
Business
/
Masimo Q1 Non-GAAP Net Income, Revenue Decline; Q2 Guidance Set -- Shares Rise After Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Masimo Q1 Non-GAAP Net Income, Revenue Decline; Q2 Guidance Set -- Shares Rise After Hours
May 7, 2024 2:53 PM

05:28 PM EDT, 05/07/2024 (MT Newswires) -- Masimo ( MASI ) reported Q1 non-GAAP net income Tuesday of $0.77 per diluted share, down from $1.03 per share a year earlier.

Analysts polled by Capital IQ expected $0.70.

Revenue in the quarter ended March 30 fell to $492.8 million from $565 million a year earlier. Analysts surveyed by Capital IQ expected $487.7 million.

The company expects Q2 non-GAAP EPS of $0.73 to $0.79 on revenue of $480 million to $510 million. The consensus is for normalized EPS of $0.80 on revenue of $502.7 million.

For 2024, Masimo ( MASI ) raised its non-GAAP EPS estimates to $3.54 to $3.70 from previous guidance of $3.44 to $3.60. Analysts are looking for normalized EPS of $3.52.

The company expects 2024 revenue between $2.06 billion and $2.17 billion. Analysts polled by Capital IQ expect $2.10 billion.

The company's shares rose 1.1% in after-hours activity.

Price: 137.45, Change: +1.45, Percent Change: +1.07

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting
Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting
Aug 22, 2025
Biohaven Ltd. ( BHVN ) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA). In May 2025, the Division of Neurology 1 within the Office of Neuroscience of the Food and Drug Administration (FDA) informed the company that it was extending the Prescription Drug...
Natural Gas Prices Fall as Forecasts See Cooler Weather Coming for Most States
Natural Gas Prices Fall as Forecasts See Cooler Weather Coming for Most States
Aug 22, 2025
09:10 AM EDT, 08/22/2025 (MT Newswires) -- Natural gas prices weakened early on Friday as forecasts see cooler weather on the way even as a day-prior report showed a smaller than expected rise in U.S. inventories of the fuel. Gas for September delivery was last seen down US$0.05 to US$2.77 per million British thermal units. The drop comes as long-term...
Cenovus Energy Strikes $5.68 Billion Deal to Buy MEG Energy
Cenovus Energy Strikes $5.68 Billion Deal to Buy MEG Energy
Aug 22, 2025
09:15 AM EDT, 08/22/2025 (MT Newswires) -- Cenovus Energy ( CVE ) has agreed to acquire fellow Canadian oil sands producer MEG Energy in a cash-and-stock deal worth about 7.9 billion Canadian dollars ($5.68 billion), including debt, the companies said Friday. Shareholders of MEG Energy will have the option to receive CA$27.25 per share in cash or 1.325 of Cenovus...
Hudson Global, Star Equity Complete All-Stock Merger; Hudson Shares Rise Pre-Bell
Hudson Global, Star Equity Complete All-Stock Merger; Hudson Shares Rise Pre-Bell
Aug 22, 2025
09:07 AM EDT, 08/22/2025 (MT Newswires) -- Hudson Global ( HSON ) said Friday that it completed its all-stock merger with Star Equity ( STRR ) after both companies received stockholder approval to complete the transaction. With the merger, Hudson said former holders of Star common shares received 744,291 Hudson common shares and holders of Star preferred stock received about...
Copyright 2023-2026 - www.financetom.com All Rights Reserved